Trial Profile
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs NP-001 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Neuraltus Pharmaceuticals
- 01 Feb 2022 According to a Neuraltus Pharmaceuticals, Merit Cudkowicz, M.D is the investigator of phase 2 studies.
- 01 Feb 2022 According to a Neuraltus Pharmaceuticals media release, data from this trial was published in in Peer-Reviewed Journal, Muscle & Nerve.
- 01 Feb 2022 Results published in Neuvivo Media Release.